The POWER1 Study: Exploring Innovative Solutions for Focal Onset Seizures
The POWER1 Study: Advancing Epilepsy Research with Flexible, Home-Based Participation
Focus Keyword: focal onset seizures clinical trial
What is the POWER1 Study?
The POWER1 Study evaluates a new investigational medication, vormatrigine, for adults with focal onset seizures. Participants can contribute to cutting-edge epilepsy research while potentially gaining access to a promising treatment.
Why Join the POWER1 Study?
- Convenient Participation:
Most visits can be completed from home. This flexibility reduces travel and fits seamlessly into participants’ routines. - No-Cost Care:
All study-related care, including travel costs, is covered. No insurance is required. - Expert Oversight:
Participants receive close monitoring by experienced doctors and study staff who prioritize safety.
Eligibility Criteria:
- Age: 18–75
- Currently experience focal onset seizures
- Taking at least one anti-seizure medication
If you meet these criteria, start by answering a brief health questionnaire. If eligible, a trial navigator will guide you through the enrollment process. After joining, you’ll receive detailed instructions for any at-home tasks, appointments, and visits.
How This Study Helps Epilepsy Research
Your involvement supports the evaluation of vormatrigine and advances medical knowledge. While you receive dedicated care, you also contribute to a potential new treatment that could benefit many others living with epilepsy.
Get Started Today
Take the first step toward participating in this focal onset seizures clinical trial. Visit the POWER1 Study website or Arizona Neuroscience Research for more information.
Meta Description:
Learn about the POWER1 Study, a focal onset seizures clinical trial evaluating vormatrigine. Join now and help advance epilepsy research.
# New Seizure Study Arizona Treatment
